Maat Pharma SA (MAAT) EUR0.1

Sell:€4.28Buy:€4.36€0.15 (3.56%)

Prices delayed by at least 15 minutes
Sell:€4.28
Buy:€4.36
Change:€0.15 (3.56%)
Deal now
Prices delayed by at least 15 minutes
Sell:€4.28
Buy:€4.36
Change:€0.15 (3.56%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Maat Pharma SA is a France-based company, which is engaged into research and development in biotechnology sector. The Company specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.

Key people

Jean-Marie Lefevre
Chairman of the Board
Herve Affagard
Chief Executive Officer, Co-Founder, Director
Eric Soyer
Chief Financial Officer
Carole Schwintner
Chief Technology Officer
Sheri Simmons
Acting Chief Scientific Officer
Jonathan Chriqui
Chief Business Officer
Frederic Fasano
Chief Strategy and Corporate Development Officer
Behzad Kharabi Masouleh
Acting Chief Medical Officer
Emilie Plantamura
Deputy Chief Medical Officer
Isabelle De Cremoux
Non-Executive Director
Muriel Prudent
Non-Executive Director
Claude Bertrand
Independent Director
Dorothee Burkel
Independent Director
Nadia Kamal
Independent Director
Click to see more

Key facts

  • Shares in issue
    16.14m
  • EPIC
    MAAT
  • ISIN
    FR0012634822
  • Location
    France
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    €67.93m
  • Employees
    60
  • Exchange
    Euronext Paris
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.